Empowered Patient Podcast

Karen Jagoda
  • 4,9 (17)
  • МЕДИЦИНА
  • ЕЖЕДНЕВНО

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. -11 Ч · БОНУСНЫЙ КОНТЕНТ

    Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx TRANSCRIPT

    Michael Palladino, VP of Sales and Clinical Solutions at OptimizeRx, is utilizing AI to educate patients and providers, promoting shared decision-making about which medications are most likely to yield the best health outcomes. The goal is to combat information overload by precisely targeting education to specific patients and delivering that information on the patient's preferred media delivery platform.  Technology-driven nudges deliver timely information, reminders about upcoming appointments, and address medication adherence issues.  Michael explains, "So OptimizeRx is a health technology company. We partner with the life sciences industry, and we help patients get on the right drug at the right time, educating both patient and provider. And we do that through some traditional methods of point-of-care. We also use our AI technology, which we will talk a little bit about today." "We've evolved as a company to be as individualized as possible, and that really has been using the technological advances of AI and machine learning over the past three years to predict in a patient journey when they may qualify for a procedure or drug, and educating both the patient and the HCP. So, it's really the use of data and technology that has evolved, and it's how we're leveraging our expertise in the space." "Traditionally, the way that a pharmaceutical industry may work or a life science manufacturer may work is they're often quite siloed. The patient gets some type of education on TV, the HCP somewhere in the country gets a similar type of education, and there's not a lot of synergy. What we have done in the marketplace is combine the patient's finding with the HCP's finding, and we educate them at the right time."  #OptimizeRx #PrecisionMedicine #HealthTech #AI #HealthAI #DrugInformation optimizerx.com Listen to the podcast here

  2. -11 Ч

    Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx

    Michael Palladino, VP of Sales and Clinical Solutions at OptimizeRx, is utilizing AI to educate patients and providers, promoting shared decision-making about which medications are most likely to yield the best health outcomes. The goal is to combat information overload by precisely targeting education to specific patients and delivering that information on the patient's preferred media delivery platform.  Technology-driven nudges deliver timely information, reminders about upcoming appointments, and address medication adherence issues.  Michael explains, "So OptimizeRx is a health technology company. We partner with the life sciences industry, and we help patients get on the right drug at the right time, educating both patient and provider. And we do that through some traditional methods of point-of-care. We also use our AI technology, which we will talk a little bit about today." "We've evolved as a company to be as individualized as possible, and that really has been using the technological advances of AI and machine learning over the past three years to predict in a patient journey when they may qualify for a procedure or drug, and educating both the patient and the HCP. So, it's really the use of data and technology that has evolved, and it's how we're leveraging our expertise in the space." "Traditionally, the way that a pharmaceutical industry may work or a life science manufacturer may work is they're often quite siloed. The patient gets some type of education on TV, the HCP somewhere in the country gets a similar type of education, and there's not a lot of synergy. What we have done in the marketplace is combine the patient's finding with the HCP's finding, and we educate them at the right time."  #OptimizeRx #PrecisionMedicine #HealthTech #AI #HealthAI #DrugInformation optimizerx.com Download the transcript here

    20 мин.

  3. -1 ДН. · БОНУСНЫЙ КОНТЕНТ

    Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion TRANSCRIPT

    Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting.  Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate security hygiene for the entire printer fleet. Jim explains, "We personally were exposed to the print industry in about 2015. And we noticed that the printers are really essential for patient care. They process, store, and transmit the most sensitive data, but they have grown up outside of the information security and supply chain. The security has been left vulnerable. In today's cybercrime growth industry climate, where opportunistic criminals are looking for opportunities to steal data, ransom, or attack patient care, you've got a real recipe for disaster. So really, we're facing a whole lot of issues that relate to the vulnerability of the printer." "They're absolutely very complex business machines, and the manufacturers for the last 40 years or so, from what you're talking about, the analog days, have really enriched them with incredible features beyond the camera, the document sorter, and things like that. They built in incredible web server features, email servers, fax servers, FTP servers, like a Dropbox that we all use for heavy payload communication protocols. They built all those features into the devices, and they built in ways to secure those features, but they haven't been used, and they're not being used on networks."  #Symphion #Hospitals #PrinterSecurity #Cybercrimes #NetworkSecurity symphion.com Listen to the podcast here

  4. -1 ДН.

    Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion

    Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting.  Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate security hygiene for the entire printer fleet. Jim explains, "We personally were exposed to the print industry in about 2015. And we noticed that the printers are really essential for patient care. They process, store, and transmit the most sensitive data, but they have grown up outside of the information security and supply chain. The security has been left vulnerable. In today's cybercrime growth industry climate, where opportunistic criminals are looking for opportunities to steal data, ransom, or attack patient care, you've got a real recipe for disaster. So really, we're facing a whole lot of issues that relate to the vulnerability of the printer." "They're absolutely very complex business machines, and the manufacturers for the last 40 years or so, from what you're talking about, the analog days, have really enriched them with incredible features beyond the camera, the document sorter, and things like that. They built in incredible web server features, email servers, fax servers, FTP servers, like a Dropbox that we all use for heavy payload communication protocols. They built all those features into the devices, and they built in ways to secure those features, but they haven't been used, and they're not being used on networks."  #Symphion #Hospitals #PrinterSecurity #Cybercrimes #NetworkSecurity symphion.com Download the transcript here

    19 мин.

  5. -2 ДН. · БОНУСНЫЙ КОНТЕНТ

    How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech TRANSCRIPT

    Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think of hydrogels like sponges. They're super absorbent, bio-friendly materials that are made of water. For this reason, scientists like myself essentially consider them the next best thing to natural tissue. Just like our own bodies, they're mostly made up of water. They have great applications in drug delivery, implant cosmetics, all these modern hydrogel face masks, and other types of substances." "I worked in hydrogel research for many years after seeing my mother and both my grandmothers go through chemotherapy treatments. I became motivated to make these treatments more effective, smarter, more targeted, and hydrogel-like. I just realized the main limitation is that to even make one of these treatments, it costs the company around a billion dollars over 10 years to figure out if this hydrogel is even going to work. And most of this was due to manual testing. It's scientists doing the same tests over and over again. It's very tedious, takes a long time, and it's very expensive to get a scientist to do this all day, every day. After feeling like a robot during the same test over and over again, I said, ‘I want to build a robot that automates this.' The company I was working for loved it and I essentially started focusing on that for the rest of my career."  #GelTech #Hydrogels #Robots #ResearchRobotics #Cancer #CancerTreatments geltechlabs.com Listen to the podcast here

  6. -2 ДН.

    How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech

    Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think of hydrogels like sponges. They're super absorbent, bio-friendly materials that are made of water. For this reason, scientists like myself essentially consider them the next best thing to natural tissue. Just like our own bodies, they're mostly made up of water. They have great applications in drug delivery, implant cosmetics, all these modern hydrogel face masks, and other types of substances." "I worked in hydrogel research for many years after seeing my mother and both my grandmothers go through chemotherapy treatments. I became motivated to make these treatments more effective, smarter, more targeted, and hydrogel-like. I just realized the main limitation is that to even make one of these treatments, it costs the company around a billion dollars over 10 years to figure out if this hydrogel is even going to work. And most of this was due to manual testing. It's scientists doing the same tests over and over again. It's very tedious, takes a long time, and it's very expensive to get a scientist to do this all day, every day. After feeling like a robot during the same test over and over again, I said, ‘I want to build a robot that automates this.' The company I was working for loved it and I essentially started focusing on that for the rest of my career."  #GelTech #Hydrogels #Robots #ResearchRobotics #Cancer #CancerTreatments geltechlabs.com Download the transcript here

    17 мин.

  7. -5 ДН. · БОНУСНЫЙ КОНТЕНТ

    Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT

    Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction in their meibomian glands, and they can't make enough tears or those tears aren't the right composition. But more than half of the patients with dry eye have an underlying autoimmune disease. And they might know that, and they might not. So, patients with either Sjogren's disease or any of the thyroid conditions, patients with rheumatoid arthritis, MS, connective tissue dysfunction, most of those patients have some ocular comorbidities, and specifically, dry eye is probably one of the biggest ones." "Sometimes we treat the body, and we can treat autoimmune diseases successfully, but you don't really get most drugs into the eye. And so those alarm bells are still going off in the eye. And unfortunately, these patients with autoimmune disease tend to have more severe disease. They respond differently to the drugs that are out there today and probably most troublesome to us, and why Iolyx is really targeted these patients is that they get excluded from most of trials because they're just more difficult to treat, but they're also more difficult to treat because they have systemic medications that they're on, and most of those drugs get excluded." #IolyxTherapeutics #DryEyeDisease #Ophthalmology #AutoimmuneDisease #EyeCare #ImmunoOphthalmology #ClinicalTrials Iolyx.com Listen to the podcast here

  8. -5 ДН.

    Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx

    Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction in their meibomian glands, and they can't make enough tears or those tears aren't the right composition. But more than half of the patients with dry eye have an underlying autoimmune disease. And they might know that, and they might not. So, patients with either Sjogren's disease or any of the thyroid conditions, patients with rheumatoid arthritis, MS, connective tissue dysfunction, most of those patients have some ocular comorbidities, and specifically, dry eye is probably one of the biggest ones." "Sometimes we treat the body, and we can treat autoimmune diseases successfully, but you don't really get most drugs into the eye. And so those alarm bells are still going off in the eye. And unfortunately, these patients with autoimmune disease tend to have more severe disease. They respond differently to the drugs that are out there today and probably most troublesome to us, and why Iolyx is really targeted these patients is that they get excluded from most of trials because they're just more difficult to treat, but they're also more difficult to treat because they have systemic medications that they're on, and most of those drugs get excluded." #IolyxTherapeutics #DryEyeDisease #Ophthalmology #AutoimmuneDisease #EyeCare #ImmunoOphthalmology #ClinicalTrials Iolyx.com Download the transcript here

    18 мин.
См. все (2 тыс.)

4,9
из 5
Оценок: 17

Об этом подкасте

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Информация

  • Автор
    Karen Jagoda
  • Годы выхода
    2015 - 2025
  • Выпуски
    2 тыс.
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2024
  • Сайт подкаста
    Empowered Patient Podcast

Вам может также понравиться